Drug Trial Radar · NCT03745651
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
618
Actual
Start
Dec 20, 2018
Primary completion
Nov 18, 2019
Study completion Nov 9, 2020
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Nov 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
Ruxolitinib creamDrug
Ruxolitinib 0.75% or 1.5% cream.
Vehicle creamDrug
Ruxolitinib matching vehicle cream.
Primary outcomes
What the sponsor says the trial is designed to measure.
- VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8Time frame: Baseline to Week 8
Locations
66 sites in 7 countries. Site status is shown where the registry gives one.
University Of Alabama At Birmingham
Birmingham, Alabama
Center For Dermatology Cosmetic And Laser Surgery
Fremont, California
Marvel Clinical Research - Clinedge - PPDS
Huntington Beach, California
Allergy And Asthma Associates Of Southern California - CRN
Mission Viejo, California
Synexus Clinical Research US Inc. Santa Rosa
Santa Rosa, California
Olympian Clinical Research
Largo, Florida
San Marcus Research Clinic Inc
Miami Lakes, Florida
Well Pharma Medical Research Corporation
South Miami, Florida
Forward Clinical Trials Inc
Tampa, Florida
Clinical Research Atlanta - ERN - PPDS
Stockbridge, Georgia
Northwest Clinical Trials Clinedge
Boise, Idaho
Randall Dermatology
West Lafayette, Indiana
Derm Research LLC
Louisville, Kentucky
Dermatology Specialists PSC
Louisville, Kentucky
Michael W Simon MD Office
Nicholasville, Kentucky
Delricht Clinical Research - Clinedge - PPDS Baton Rouge
Baton Rouge, Louisiana
Hamzavi Dermatology
Fort Gratiot, Michigan
Jubilee Clinical Research - BTC - PPDS
Las Vegas, Nevada
ActivMed Practices & Research Inc
Portsmouth, New Hampshire
Hassman Research Institute
Berlin, New Jersey
Skin Laser and Surgery specialists of New York and New Jersey LLC
Hackensack, New Jersey
Derm Research Center Of New York Inc
Stony Brook, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Synexus Clinical Research US, Inc. - Cincinnati
Cincinnati, Ohio
Ohio Pediatric Research Association
Dayton, Ohio
Synexus Clinical Research US, Inc. - Anderson
Anderson, South Carolina
International Clinical Research Tennessee LLC
Murfreesboro, Tennessee
Epiphany Dermatology Fort Worth
Fort Worth, Texas
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas
Center for Clinical Studies
Webster, Texas
Tanner Clinic
Layton, Utah
Advanced Research Institute
Ogden, Utah
PI Coor Clinical Research LLC
Burke, Virginia
Clinical Research Partners LLC
Richmond, Virginia
Dermatology Specialists of Spokane
Spokane, Washington
Medical Center Excelsior OOD - PPDS
Sofia, Bulgaria
Diagnostic Consultative Center XXVIII - Sofia - EOOD
Sofia, Bulgaria
Synexus - Medical Center Synexus Sofia EOOD
Sofia, Bulgaria
Synexus - Medical Centre Synexus Sofia EOOD (branch - Stara Zagora)
Stara Zagora, Bulgaria
Medical Center Unimed EOOD
Sevlievo, Gabrovo, Bulgaria
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.